Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 8.5 Contact Hours.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from Ariad Pharmaceuticals, Inc., Astellas, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Lilly, Merck Sharp & Dohme Corp., Novartis, and Pfizer.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
11th Annual New York Lung Cancer Symposium®
November 12, 2016
Crowne Plaza® Times Square Manhattan
New York, NY
The 11th Annual New York Lung Cancer Symposium® is a 1-day educational and scientific meeting that will provide an update on state-of-the-art management of patients with lung cancer, as well as a focus on future therapies in development.
The past decade in lung cancer research has yielded a wealth of therapeutic options for patients with lung cancer, as well as greater knowledge of the many different subtypes of this disease. In particular, agents targeting oncogenic drivers and immunotherapeutic approaches have both transformed the management of patients with lung cancer in recent years. Furthermore, numerous investigational approaches are in late-phase evaluation, with the potential to change standards of care in 2016 and beyond. However, although these developments hold the promise to further improve outcomes for patients with lung cancer, they also raise challenges for busy clinicians to maintain state-of-the-art approaches in their practices.
This year’s program, led by world-class thoracic oncologists Mark G. Kris, MD, and Roman Perez-Soler, MD, will focus on a number of core areas that are key to optimizing care for patients with lung cancer, including targeted therapy, immunotherapy, adjuvant therapy, combined modality therapy, and approaches for challenging subtypes, such as squamous lung cancer. Participants will have an opportunity to learn from engaging presentations delivered by leading experts, as well as apply their knowledge in case-based panel discussions. This fast-paced, highly practical, and interactive forum will once again provide physicians who treat patients with lung cancer unique access to renowned international experts in the management of these tumors.
This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.
Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.